2023 / 03

DOI: 10.47183/mes.2023.041

ORIGINAL RESEARCH

Catamnesis of children with congenital cytomegalovirus infection depending on etiotropic therapy in the first year of life

Vasilyev VV1,2, Rogozina NV1, Markin IV1, Ivanova RA1,3, Grineva AA4
About authors

1 Pediatric Research and Clinical Center of Infectious Diseases, Federal Medical Biological Agency, St. Petersburg, Russia

2 North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia, St. Petersburg, Russia

3 Pavlov First State Medical University of St. Petersburg, St. Petersburg, Russia

4 Almazov National Medical Research Center, Ministry of Health of Russia, St. Petersburg, Russia

Correspondence should be addressed: Valery V. Vasilyev
Mirgorodskaya, 3, korp. I, St. Petersburg, 191167, Russia; ur.ay@debucv

About paper

Funding: this study was performed under the research effort № 021-03 "Antenatal and early postnatal etiological diagnostics and etiotropic therapy of congenital infectious diseases of viral etiology" managed by the FMBA.

Author contribution: Vasilyev VV, Rogozina NV — study conceptualization and design; AA Grineva, Ivanova RA, Markin IV — collection and processing of the material, statistical data processing; Vasilyev VV, Rogozina NV — collection of literature data, article authoring, editing.

Received: 2023-08-12 Accepted: 2023-09-19 Published online: 2023-09-30
|
Fig. 1. Clinical manifestations in children with congenital cytomegalovirus infection
Fig. 2. Average values (µ) of ALT, AAT and direct bilirubin levels before therapy, after therapy and after 1 year
Fig. 3. ROC curve characterizing probability of an adverse outcome depending on the timing of DAAD therapy initiation
Fig. 4. ROC curve characterizing probability of an adverse outcome depending on the timing of anti-CMV IG therapy initiation
Table 1. Pediatric scale of outcomes of purulent meningitis
Table 2. Clinical manifestations in children with congenital cytomegalovirus infection, groups 1 and 2
Table 3. Clinical manifestations of congenital cytomegalovirus infection depending on the course of the disease
Table 4. Neuropsychiatric deficit in children with congenital CMVI before and after DAAD therapy
Table 5. Neuropsychiatric deficit in children with congenital CMVI before and after anti-CMV IG therapy
Table 6. Factors associated with an adverse outcome of congenital cytomegalovirus infection